Development of a Combined Lipid-Based Nanoparticle Formulation for Enhanced siRNA Delivery to Vascular Endothelial Cells

  • Pharmaceutics. 2022 Sep 29;14(10):2086. doi: 10.3390/pharmaceutics14102086.
Yutong He  1 Dongdong Bi  2 Josée A Plantinga  1 Grietje Molema  1 Jeroen Bussmann  2 Jan A A M Kamps  1
Affiliations
  • 1. Laboratory for Endothelial Biomedicine & Vascular Drug Targeting Research, Medical Biology Section, Department of Pathology & Medical Biology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands.
  • 2. Division of BioTherapeutics, Leiden Academic Centre for Drug Research (LACDR), Leiden University, 2300 RA Leiden, The Netherlands.
Abstract

Low transfection efficiency in endothelial cells (EC) is still a bottleneck for the majority of siRNA-based vascular delivery approaches. In this work, we developed a lipid-based nanoparticle (LNP) formulation based on a combination of a permanently charged cationic lipid-DOTAP and a conditionally ionized cationic lipid-MC3 (DOTAP/MC3) for the enhanced delivery of siRNA into EC. Compared with a single DOTAP or MC3-based benchmark LNP, we demonstrated that the DOTAP/MC3 LNP formulation shows the best transfection efficiency both in primary EC in vitro and in endothelium in zebrafish. The high transfection activity of the DOTAP/MC3 LNP formulation is achieved by a combination of improved endothelial association mediated by DOTAP and MC3-triggered efficient siRNA intracellular release in EC. Furthermore, AbVCAM-1-coupled DOTAP/MC3 LNP-mediated siRNARelA transfection showed pronounced anti-inflammatory effects in inflammatory-activated primary EC by effectively blocking the NF-κB pathway. In conclusion, the combination of permanent and ionizable Cationic Lipids in LNP formulation provides an effective endothelial cell delivery of siRNA.

Keywords
cationic lipid formulation; endothelial cell delivery; lipid-based nanoparticles; siRNA therapy; zebrafish model.
Products
Inhibitors & Agonists
Other Products